STOCK TITAN

Alpha Tau Medical Ltd - DRTS STOCK NEWS

Welcome to our dedicated news page for Alpha Tau Medical (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alpha Tau Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alpha Tau Medical's position in the market.

Rhea-AI Summary
Alpha Tau Medical announces that former FDA Commissioner Dr. Stephen M. Hahn has joined its Scientific Advisory Board. Dr. Hahn's expertise will be valuable as the company advances its Alpha DaRT technology towards FDA clearance and explores new indications for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
management
-
Rhea-AI Summary
Alpha Tau Medical announces successful treatment of patient with advanced inoperable pancreatic cancer using Alpha DaRT therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
Rhea-AI Summary
Alpha Tau Medical reports positive outcomes in feasibility trials and receives land grant for future headquarters
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
Rhea-AI Summary
Alpha Tau Medical Ltd. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
conferences
-
Rhea-AI Summary
Initial long-term safety and tumor control outcomes for patients treated with Alpha DaRT showed 89% complete response rate and 77% two-year local recurrence-free survival rate. No grade 3 or higher acute or late toxicities observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announces that Raphi Levy, Chief Financial Officer, will present at the Emerging Growth Conference on August 9th, 2023, to discuss the innovative alpha-radiation cancer therapy Alpha DaRT™. The event will take place virtually, with an archived webcast available for those unable to attend live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences acquisition
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
-
Rhea-AI Summary
Alpha Tau Medical has announced the treatment of the first patient in a feasibility and safety study of its alpha-radiation cancer therapy, Alpha DaRT, for the treatment of squamous cell carcinoma of the vulva. The trial aims to recruit 10 participants and will assess safety, feasibility, efficacy, and patient outcomes. This trial is part of Alpha Tau's strategy to expand the use of Alpha DaRT in other hard-to-treat indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
Rhea-AI Summary
Alpha Tau Medical announces successful results of pilot trial for Alpha DaRT therapy in treating skin cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Alpha Tau Medical Ltd

Nasdaq:DRTS

DRTS Rankings

DRTS Stock Data

196.47M
51.74M
25.72%
2.74%
0.08%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
Israel
Jerusalem

About DRTS

alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.